🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ATOMIC has achieved 82% accrual and needs another 126 patients to reach 700. German AIO group is now open to accrual as well. Please continue to support this potentially practice changing study. With your continued support, we’ll reach the finish line.

Meta-analysis of low quality studies is still low quality data but that's unfortunately the reality we have to live with in NEC therapy. Kudos to the authors for sorting through the data of chemo in NECs. ORR∼50%, OS∼13 mos and PFS∼5m Patrick McGarrah, MD ncbi.nlm.nih.gov/pmc/articles/P…

Thank you Blood Cancers Today for the spotlight on VSV- #Virotherapy. Exciting prelim results and we are currently recruiting for the combination arms with #virotherapy for TCL AND MM. Vincent Rajkumar Mayo Clinic Comprehensive Cancer Center Taxiarchis Kourelis Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Leif Bergsagel

As of today, the COMPOSE phase III RCT is open at Mayo Clinic in Rochester! PRRT with Lu-177 edotreotide (DOTATOC) vs. CAPTEM, FOLFOX or everolimus for 1st or 2nd line therapy for advanced high-risk G2 NETs (Ki67 15-20%) or well diff G3 NETs ≤ 55%. oncologypro.esmo.org/meeting-resour…

Another fantastic presentation, this time by Pamela Kunz, MD, FASCO, president of NANETS. Some trials to watch, including trials led by junior investigators. Very exciting times for NENs.

Just in time for #GI23 . . . the formatted #E2211 manuscript has been published in Journal of Clinical Oncology! Grateful for the opportunity to lead this trial with amazing co-authors. Bringing more treatments to pts with #pNETs. ECOG-ACRIN Cancer Research Group Yale Cancer Center PDF: bit.ly/3H15BRh

PRODIGE-41/BEVANEC: No benefit of bevacizumab + FOLFIRI following platinum/etoposide in NECs. No surprises there. Two main messages: 1) FOLFIRI works (or Nal-Iri as per NET-02) but the efficacy is very modest; 2) We have to do better for our NEC pts... thelancet.com/journals/lanon…

Should we do liquid bx in all NEC pts in addition to tumor tissue NGS? The answer may be yes. Of the mutations detected in liquid bx, only 71% were seen in tumor tissue and 18% of pts had potentially targetable mutations in liquid only. Aurel Perren ascopubs.org/doi/full/10.12…

Can one distill systemic therapy of gastroenteropancreatic NETs down to one slide...? Preparing for AHPBA next week. I have 8 min to cover systemic therapy of NETs. The final slide works better in presentation mode but here it is. Anything missing...? #neuroendocrinetumors

Hot off the press! NENs of the urinary system. Multi-center retrospective study. Great work led by Bryan Le at UCSF. It took a village to get this done... Patrick McGarrah, MD Diane Reidy-Lagunes Emily bergsland Jaydira Del Rivero, MD Andrea Apolo, M.D. David Chan clinical-genitourinary-cancer.com/article/S1558-…

aacrjournals.org/cancerres/arti… Interesting results dual CPI of Porustobart+toripalimab IN G3 NEN (11 NEC+5 NETG3). ORR 37.5% DCR 72.7%. Grade 3 TRAE in 1/3 pts #NEC #neuroendocrine

Genomics IS the diagnosis

Should we add ICIs to platinum/etoposide chemo in extrapulmonary NECs? My answer is NO, not outside of a trial. This retrospective study led by Jennifer Gile, M.D. did not report benefit. Please, please keep SWOG S2012 in mind and enroll whenever possible!! onlinelibrary.wiley.com/doi/10.1111/jn…

Wondering what to do beyond 1st line chemo for poorly diff extrapulm NEC. The answers might be in here... Thanks to the team, especially Nick Andreatos who led the project (and is not on X) and Patrick McGarrah, MD Bassam Sonbol @drjasonstarr Jaume Capdevila link.springer.com/article/10.100…

Trial Alert! ACTION-1 is now open at all three Mayo Clinic sites. Phase III trial of alpha particle PRRT w/ Ac-225 DOTATATE vs. provider's choice of SOC therapy for pts w/ progressive G1/G2 GEPNETs and prior Lu-177 PRRT. Very simplified schema below clinicaltrials.gov/study/NCT05477…

SBRT for malignant insulinoma... Refractory hypoglycemia + oligomet liver progression. Prior hepatic artery embolizations effective but no longer. On SSA, intolerant to everolimus. 50 Gy SBRT to the prog liver lesions with complete resolution of hypoglycemia. Patrick McGarrah, MD

Explore a rare neuroendocrine carcinoma case, demonstrating the success of precision oncology guided by HER2 genomic profiling. This emphasizes innovative treatments and advocates for broader HER2-positive clinical trial inclusion. #Oncology 🩺✨ ascopubs.org/doi/10.1200/PO…

Check this out 📝📌 HER2 NEC + Precision Genomics. One of the biggest accomplishments of the year 🙏🏼 #Oncology Mayo Clinic

Orbital metastases from well diff NETs are well known and the primary NET is usually in the small bowel. This patient presented w/ mild diplopia on left horizonal gaze (had known SB NET). Small metastasis in the left lateral rectus muscle. Radiotherapy is very effective and safe.

Poorly differentiated NECs remains a terrible disease with a short overall survival and a dire need for better therapy options. Excellent presentation from the NORDIC NEC study by Dr. Halfdan Sorbye. #ENETS24